GSK (GSK) Competitors

GSK logo
GBX 1,842.50 +15.50 (+0.85%)
As of 11/20/2026 11:58 AM Eastern

GSK vs. AZN, BMK, DPH, HIK, and INDV

Should you buy GSK stock or one of its competitors? GSK's main competitors and comparable companies include AstraZeneca (AZN), Benchmark (BMK), Dechra Pharmaceuticals (DPH), Hikma Pharmaceuticals (HIK), and Indivior (INDV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does GSK compare to AstraZeneca?

GSK (LON:GSK) and AstraZeneca (LON:AZN) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

GSK has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.212, meaning that its share price is 79% less volatile than the broader market.

AstraZeneca has a net margin of 17.69% compared to GSK's net margin of 12.97%. GSK's return on equity of 24.64% beat AstraZeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
GSK12.97% 24.64% 9.56%
AstraZeneca 17.69%22.31%7.68%

56.9% of GSK shares are owned by institutional investors. Comparatively, 67.8% of AstraZeneca shares are owned by institutional investors. 0.2% of GSK shares are owned by insiders. Comparatively, 0.2% of AstraZeneca shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, GSK had 6 more articles in the media than AstraZeneca. MarketBeat recorded 14 mentions for GSK and 8 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 0.06 beat GSK's score of -0.07 indicating that AstraZeneca is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GSK
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
6 Negative mention(s)
1 Very Negative mention(s)
Neutral
AstraZeneca
0 Very Positive mention(s)
5 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GSK£33.54B2.20£2.50B£106.9017.24
AstraZeneca£62.38B3.33£8.71B£706.0019.00

GSK presently has a consensus price target of GBX 2,145, indicating a potential upside of 16.42%. AstraZeneca has a consensus price target of £155.50, indicating a potential upside of 15.94%. Given GSK's higher probable upside, equities research analysts clearly believe GSK is more favorable than AstraZeneca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GSK
1 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.25
AstraZeneca
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

GSK pays an annual dividend of GBX 68 per share and has a dividend yield of 3.7%. AstraZeneca pays an annual dividend of GBX 322.05 per share and has a dividend yield of 2.4%. GSK pays out 63.6% of its earnings in the form of a dividend. AstraZeneca pays out 45.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

AstraZeneca beats GSK on 11 of the 18 factors compared between the two stocks.

How does GSK compare to Benchmark?

GSK (LON:GSK) and Benchmark (LON:BMK) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

GSK has a net margin of 12.97% compared to Benchmark's net margin of -43.67%. GSK's return on equity of 24.64% beat Benchmark's return on equity.

Company Net Margins Return on Equity Return on Assets
GSK12.97% 24.64% 9.56%
Benchmark -43.67%-15.96%-1.07%

In the previous week, GSK had 14 more articles in the media than Benchmark. MarketBeat recorded 14 mentions for GSK and 0 mentions for Benchmark. Benchmark's average media sentiment score of 0.00 beat GSK's score of -0.07 indicating that Benchmark is being referred to more favorably in the news media.

Company Overall Sentiment
GSK Neutral
Benchmark Neutral

56.9% of GSK shares are owned by institutional investors. Comparatively, 13.3% of Benchmark shares are owned by institutional investors. 0.2% of GSK shares are owned by insiders. Comparatively, 63.7% of Benchmark shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

GSK has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, Benchmark has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

GSK presently has a consensus price target of GBX 2,145, indicating a potential upside of 16.42%. Given GSK's stronger consensus rating and higher probable upside, equities research analysts clearly believe GSK is more favorable than Benchmark.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GSK
1 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.25
Benchmark
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

GSK has higher revenue and earnings than Benchmark. GSK is trading at a lower price-to-earnings ratio than Benchmark, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GSK£33.54B2.20£2.50B£106.9017.24
Benchmark£79.16M1,189.43-£39.55M£0.06246,774.19

Summary

GSK beats Benchmark on 11 of the 16 factors compared between the two stocks.

How does GSK compare to Dechra Pharmaceuticals?

GSK (LON:GSK) and Dechra Pharmaceuticals (LON:DPH) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

GSK pays an annual dividend of GBX 68 per share and has a dividend yield of 3.7%. Dechra Pharmaceuticals pays an annual dividend of GBX 45 per share. GSK pays out 63.6% of its earnings in the form of a dividend. Dechra Pharmaceuticals pays out -18,000.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

GSK has higher revenue and earnings than Dechra Pharmaceuticals. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GSK£33.54B2.20£2.50B£106.9017.24
Dechra Pharmaceuticals£761.50M0.00-£27.90M-£0.25N/A

GSK has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market. Comparatively, Dechra Pharmaceuticals has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

GSK currently has a consensus target price of GBX 2,145, indicating a potential upside of 16.42%. Given GSK's stronger consensus rating and higher possible upside, equities analysts clearly believe GSK is more favorable than Dechra Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GSK
1 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.25
Dechra Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, GSK had 14 more articles in the media than Dechra Pharmaceuticals. MarketBeat recorded 14 mentions for GSK and 0 mentions for Dechra Pharmaceuticals. Dechra Pharmaceuticals' average media sentiment score of 0.00 beat GSK's score of -0.07 indicating that Dechra Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
GSK Neutral
Dechra Pharmaceuticals Neutral

GSK has a net margin of 12.97% compared to Dechra Pharmaceuticals' net margin of -3.66%. GSK's return on equity of 24.64% beat Dechra Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
GSK12.97% 24.64% 9.56%
Dechra Pharmaceuticals -3.66%-3.92%0.75%

56.9% of GSK shares are owned by institutional investors. Comparatively, 105.5% of Dechra Pharmaceuticals shares are owned by institutional investors. 0.2% of GSK shares are owned by insiders. Comparatively, 9.3% of Dechra Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

GSK beats Dechra Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does GSK compare to Hikma Pharmaceuticals?

Hikma Pharmaceuticals (LON:HIK) and GSK (LON:GSK) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Hikma Pharmaceuticals pays an annual dividend of GBX 82.48 per share and has a dividend yield of 4.9%. GSK pays an annual dividend of GBX 68 per share and has a dividend yield of 3.7%. Hikma Pharmaceuticals pays out 46.9% of its earnings in the form of a dividend. GSK pays out 63.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Hikma Pharmaceuticals is clearly the better dividend stock, given its higher yield and lower payout ratio.

Hikma Pharmaceuticals currently has a consensus price target of GBX 1,986.25, indicating a potential upside of 17.81%. GSK has a consensus price target of GBX 2,145, indicating a potential upside of 16.42%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Hikma Pharmaceuticals is more favorable than GSK.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hikma Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
GSK
1 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.25

Hikma Pharmaceuticals has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, GSK has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

In the previous week, GSK had 12 more articles in the media than Hikma Pharmaceuticals. MarketBeat recorded 14 mentions for GSK and 2 mentions for Hikma Pharmaceuticals. Hikma Pharmaceuticals' average media sentiment score of 0.00 beat GSK's score of -0.07 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hikma Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
GSK
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
6 Negative mention(s)
1 Very Negative mention(s)
Neutral

GSK has higher revenue and earnings than Hikma Pharmaceuticals. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hikma Pharmaceuticals£3.42B1.02£353.21M£176.009.58
GSK£33.54B2.20£2.50B£106.9017.24

63.6% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 56.9% of GSK shares are held by institutional investors. 22.3% of Hikma Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of GSK shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

GSK has a net margin of 12.97% compared to Hikma Pharmaceuticals' net margin of 11.31%. GSK's return on equity of 24.64% beat Hikma Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hikma Pharmaceuticals11.31% 15.05% 9.40%
GSK 12.97%24.64%9.56%

Summary

Hikma Pharmaceuticals beats GSK on 10 of the 18 factors compared between the two stocks.

How does GSK compare to Indivior?

Indivior (LON:INDV) and GSK (LON:GSK) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

In the previous week, GSK had 14 more articles in the media than Indivior. MarketBeat recorded 14 mentions for GSK and 0 mentions for Indivior. Indivior's average media sentiment score of 0.00 beat GSK's score of -0.07 indicating that Indivior is being referred to more favorably in the media.

Company Overall Sentiment
Indivior Neutral
GSK Neutral

GSK has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indivior£1.40B1.38-£2.36M-£1.21N/A
GSK£33.54B2.20£2.50B£106.9017.24

86.0% of Indivior shares are owned by institutional investors. Comparatively, 56.9% of GSK shares are owned by institutional investors. 3.4% of Indivior shares are owned by company insiders. Comparatively, 0.2% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

GSK has a consensus price target of GBX 2,145, suggesting a potential upside of 16.42%. Given GSK's stronger consensus rating and higher probable upside, analysts clearly believe GSK is more favorable than Indivior.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indivior
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
GSK
1 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.25

Indivior has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. Comparatively, GSK has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

GSK has a net margin of 12.97% compared to Indivior's net margin of 0.17%. GSK's return on equity of 24.64% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
Indivior0.17% -1.11% 2.37%
GSK 12.97%24.64%9.56%

Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. GSK pays an annual dividend of GBX 68 per share and has a dividend yield of 3.7%. Indivior pays out -1,243.7% of its earnings in the form of a dividend. GSK pays out 63.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

GSK beats Indivior on 14 of the 18 factors compared between the two stocks.

Get GSK News Delivered to You Automatically

Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GSK vs. The Competition

MetricGSKPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£73.86B£13.62B£7.78B£2.67B
Dividend Yield3.52%2.58%2.47%5.11%
P/E Ratio17.2427.5233.2222.78
Price / Sales2.206.788.104.91
Price / Cash8.1515.6321.0120.23
Price / Book5.595.164.262.40
Net Income£2.50B£2.86B£3.50B£5.88B
1 Month Performance-1.37%-9.80%-10.48%-4.75%
1 Year Performance4.26%-8.93%-4.61%5.15%

GSK Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GSK
GSK
3.4455 of 5 stars
GBX 1,842.50
+0.8%
GBX 2,145
+16.4%
+4.8%£73.86B£33.54B17.2466,841
AZN
AstraZeneca
4.1278 of 5 stars
£139.82
+0.4%
£155.50
+11.2%
-2.0%£216.85B£62.38B19.8096,100
BMK
Benchmark
N/A£153
-0.6%
N/A+0.0%£94.15B£79.16M246,774.19823
DPH
Dechra Pharmaceuticals
N/AN/AN/AN/A£4.40B£761.50MN/A2,457
HIK
Hikma Pharmaceuticals
2.6652 of 5 stars
GBX 1,635
-0.9%
GBX 1,986.25
+21.5%
+7.8%£3.38B£3.42B9.299,500

Related Companies and Tools


This page (LON:GSK) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners